Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard N Channick

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Plos One|March 29, 2018
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trialRogério Souza, Richard N Channick, Marion Delcroix, et al.
JACC. Heart Failure|December 3, 2014
Effect of macitentan on hospitalizations: results from the SERAPHIN trialRichard N Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, et al.
Respiratory Research|December 2, 2022
Perfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarkerTilo Winkler, Puja Kohli, Vanessa J Kelly, et al.
Chest|August 13, 2011
Efficacy of methylprednisolone in preventing lung injury following pulmonary thromboendarterectomyKim M Kerr, William R Auger, James J Marsh, et al.
JMIR Research Protocols|April 13, 2021
The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal StudyKim M Kerr, C Greg Elliott, Raymond L Benza, et al.
Chest|April 30, 2018
Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY TrialKelly M Chin, Mardi Gomberg-Maitland, Richard N Channick, et al.
European Journal of Heart Failure|January 12, 2019
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON studyMaurice Beghetti, Richard N Channick, Kelly M Chin, et al.
Annals of the American Thoracic Society|April 14, 2026
Biological Sex Differences in the US-CTEPH-RMeghan M Cirulis, William R Auger, Raymond L Benza, et al.
Journal of the American College of Cardiology|June 27, 2009
Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertensionMarius M Hoeper, Joan Albert Barberà, Richard N Channick, et al.
Pulmonary Circulation|January 17, 2017
Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertensionHilary M DuBrock, Josanna M Rodriguez-Lopez, Barbara L LeVarge, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Plos One|March 29, 2018
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trialRogério Souza, Richard N Channick, Marion Delcroix, et al.
JACC. Heart Failure|December 3, 2014
Effect of macitentan on hospitalizations: results from the SERAPHIN trialRichard N Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, et al.
Respiratory Research|December 2, 2022
Perfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarkerTilo Winkler, Puja Kohli, Vanessa J Kelly, et al.
Chest|August 13, 2011
Efficacy of methylprednisolone in preventing lung injury following pulmonary thromboendarterectomyKim M Kerr, William R Auger, James J Marsh, et al.
JMIR Research Protocols|April 13, 2021
The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal StudyKim M Kerr, C Greg Elliott, Raymond L Benza, et al.
Chest|April 30, 2018
Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY TrialKelly M Chin, Mardi Gomberg-Maitland, Richard N Channick, et al.
European Journal of Heart Failure|January 12, 2019
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON studyMaurice Beghetti, Richard N Channick, Kelly M Chin, et al.
Annals of the American Thoracic Society|April 14, 2026
Biological Sex Differences in the US-CTEPH-RMeghan M Cirulis, William R Auger, Raymond L Benza, et al.
Journal of the American College of Cardiology|June 27, 2009
Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertensionMarius M Hoeper, Joan Albert Barberà, Richard N Channick, et al.
Pulmonary Circulation|January 17, 2017
Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertensionHilary M DuBrock, Josanna M Rodriguez-Lopez, Barbara L LeVarge, et al.
Pageof 11